OSE Pharma, Rafa deal

Orphan Synergy Europe granted Rafa exclusive rights to develop and commercialize Tedopi in Israel. Rafa will be responsible for obtaining regulatory approval. OSE will receive an undisclosed upfront payment and is eligible for undisclosed development milestones. The companies will equally share profits from sales in Israel. OSE declined to provide further financial terms, and Rafa could not be reached. ...